BioMed Research International · 2022 · 23 citations · 35 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyBreast Cancer PharmacotherapyCombination Cancer TherapyTargeted Cancer TherapyTargeted TherapyTyrosine Kinase InhibitorsAnticancer ActivityCancer Combination TherapyCombination TherapyCombinatorial Drug TargetingEgfr InhibitionEpidermal Growth Factor Receptor InhibitionTargeted Therapy CombinationsTriple-negative Breast Cancer Therapy
Although many anticancer drugs have been developed for triple-negative breast cancer (TNBC) treatment, there are no obvious therapies. Moreover, the combination of epidermal growth factor receptor- (EGFR-) targeted therapeutics and classical chemotherapeutic drugs has been assessed in clinical trials for TNBC treatment, but those are not yet approved. Our serial studies for newly developed herbal medicine named SH003 provide evidence of its broad effectiveness in various cancers, especially on TNBC. The current study demonstrates a synergic effect of combinatorial treatment of SH003 and docetaxel (DTX) by targeting EGFR activation. The combinatorial treatment reduced the viability of both BT-20 and MDA-MB-231 TNBC cells, displaying the synergism. The combination of SH003 and DTX also caused the synergistic effect on apoptosis. Mechanistically, the cotreatment of SH003 and DTX inhibited phosphorylation of EGFR and AKT in both BT-20 and MDA-MB-231 cells. Moreover, our xenograft mouse tumor growth assays showed the inhibitory effect of the combinatorial treatment with no effect on body weight. Our immunohistochemistry confirmed its inhibition of EGFR phosphorylation in vivo. Collectively, combinatorial treatment of SH003 and DTX has a synergistic anticancer effect at a relatively low concentration by targeting EGFR in TNBC, indicating safety and efficacy of SH003 as adjuvant combination therapy with docetaxel. Thus, it is worth testing the combinatorial effect in clinics for treating TNBC.
35
Cancer treatment and survivorship statistics, 2019
Kimberly D. Miller, Letícia Nogueira, Angela B. Mariotto et al. · CA A Cancer Journal for Clinicians · 2019 · 4.4K citations · Full text
Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer
José Baselga, Joan Albanell, Aňa Lluch et al. · Journal of Clinical Oncology · 2005 · 410 citations · Full text
Medicine, Oncology, Pharmacology +17
High EGFR gene copy number predicts poor outcome in triple-negative breast cancer
Heae Surng Park, Min Hye Jang, Eun Joo Kim et al. · Modern Pathology · 2014 · 294 citations · Full text